Takara Bio's Amyloid Precursor Protein (APP) Antibody products are affinity-purified IgG antibodies that recognize the C-terminus of human soluble APP-alpha (Cat.# 11088) and soluble APP-beta-Swedish (Cat.# 10321). The APP Antibody products are raised in mouse using synthetic peptides and can be applied to Western blot (WB) and immunohistochemical (IHC) detection (Cat.# 10321 only) as well as immunoprecipitation (IP) (Cat.# 11088 only) of human sAPP-alpha and sAPP-beta-sw.
The accumulation of amyloid beta protein plaques in the cerebral cortex in Alzheimer's disease (AD) is one of the outcomes of APP proteolytic cleavage. More than 50 different APP gene mutations can cause early-onset Alzheimer disease. Cleavage by beta- and gamma-secretase (amyloidogenic pathway) leads to production of the pathologic amyloid-beta protein as well as soluble APP-beta, while cleavage by alpha-secretase (nonamyloidogenic pathway) results in the soluble form of APP (sAPP-alpha). Different mutations in the APP gene can give rise to variants of both sAPP-alpha and sAPP-beta.